Sunitinib probably leads to lower progression‐free survival (absolute effect size estimates based on… compared with everolimus (targeted agent versus targeted agent) (moderate certainty).
Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with everolimus (targeted agent versus targeted agent) (low certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with everolimus (targeted agent versus targeted agent) (moderate certainty).
It is very uncertain whether sorafenib changes overall survival (absolute effect size estimates based on survival… compared with sunitinib (targeted agent versus targeted agent) (very low certainty).
Sunitinib probably leads to higher progression‐free survival(absolute effect size estimates based on… compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (moderate certainty).
Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (low certainty).
Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (low certainty).
The review found no eligible studies for this question.
Sunitinib probably leads to higher progression‐free survival(absolute effect size estimates based on… compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (moderate certainty).
Sunitinib probably leads to higher overall survival (absolute effect size estimates based on survival… compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (moderate certainty).
Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (low certainty).
The review found no eligible studies for this question.
Sunitinib may leads to higher progression‐free survival(absolute effect size estimates based on… compared with atezolizumab + bevacizumab (targeted agent versus immunotherapy +… (low certainty).
It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with sunitinib (targeted agent versus targeted agent) (very low certainty).
It is very uncertain whether sunitinib changes overall survival(absolute effect size estimates based on survival… compared with atezolizumab + bevacizumab (targeted agent versus immunotherapy +… (very low certainty).
It is very uncertain whether sunitinib changes serious adverse events (Grade 3 or 4) compared with atezolizumab + bevacizumab (targeted agent versus immunotherapy +… (very low certainty).
It is very uncertain whether sunitinib changes progression‐free survival (absolute effect size estimates based on… compared with IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted… (very low certainty).